Oncolytics reports positive preclinical data combining pelareorep with pan-RAS inhibitor in colorectal cancer model

PUBT · 2d ago
Oncolytics reports positive preclinical data combining pelareorep with pan-RAS inhibitor in colorectal cancer model
  • Oncolytics Biotech announced positive preclinical results for pelareorep combined with a pan-RAS inhibitor in RAS-driven colorectal cancer.
  • Results were disclosed now; no future presentation was specified.
  • Combination treatment reduced tumor growth versus control, with pelareorep activity maintained alongside RAS inhibition and no antagonism observed.
  • Benefits from pelareorep were less apparent when dosing shifted to a weekly schedule, pointing to dosing as a key development variable.
  • Work will expand across additional dosing schedules and RAS-driven models to assess whether the combination can deepen responses or delay resistance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100815PRIMZONEFULLFEED9824369) on September 10, 2026, and is solely responsible for the information contained therein.